Document is current
Any future updates will be listed below
-
Authors
Fornaro, Michele https://orcid.org/0000-0002-9647-0853
Caiazza, Claudio
Billeci, Martina
Berk, Michael
Marx, Wolfgang https://orcid.org/0000-0002-8556-8230
Balanzá-Martinez, Vicent
De Prisco, Michele https://orcid.org/0000-0002-2032-1181
Pezone, Rosanna
De Simone, Giuseppe https://orcid.org/0000-0003-0422-3415
Solini, Niccolò
Iasevoli, Felice
Berna, Fabrice
Fond, Guillaume https://orcid.org/0000-0003-3249-2030
Boyer, Laurent https://orcid.org/0000-0003-1229-6622
Carvalho, Andre Fèrrer https://orcid.org/0000-0002-2500-5671
Dragioti, Elena
FIEDOROWICZ, Jess G. https://orcid.org/0000-0003-2057-4071
de Bartolomeis, Andrea https://orcid.org/0000-0002-3188-5652
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Solmi, Marco https://orcid.org/0000-0003-4877-7233
- License Information
-
More Information
Article History
Received: 21 December 2023
Revised: 18 June 2024
Accepted: 21 June 2024
First Online: 18 July 2024
Competing interests
: MF received honoraria for his speaker activity from the American Society of Clinical Psychopharmacology (ASCP) and served as a consultant for Angelini, Otsuka, Lundbeck, Sanofi-Aventis, and Boehringer Ingelheim. WM has previously received university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. WM has received funding and/or has attended events funded by Cobram Estate Pty. Ltd and Bega Dairy and Drinks Pty Ltd. WM has received travel funding from the Nutrition Society of Australia. WM has received consultancy funding from Nutrition Research Australia and ParachuteBH. MS has received honoraria/has been a consultant for AbbVie, Angelini, Lundbeck, and Otsuka. VBM received honoraria from Angelini, unrelated to the present work. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Car dio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. All other authors declare no conflicts of interest relevant to this work.
